19625 RESULTS
COMMENT The Phase 2 data on donanemab is encouraging and raises expectations for Phase 3 trials. The effect size on the primary endpoint (iADRS score) is considerable and very promising. However, secondary endpoints such as CDR-SB, ADAS-Cog13, and MMSE were less
COMMENT The Phase 2 donanemab results are exciting and important. This innovative trial of a highly potent amyloid-normalizing antibody met its primary cognitive/functional endpoint. As with other such antibodies, a significant number of participants developed AR
COMMENT In any therapeutic trial, of course it is much nicer to detect a potential signal of efficacy than not to detect such a signal. The more limited that signal is, though, the more cautious we have to be in interpreting its basis. One possibility here is tha
COMMENT This study used a straightforward trial design with a clear outcome, which met the prespecified outcomes. The rate of amyloid-related imaging abnormalities was not trivial but the consequences were manageable. The effect size of reduction of decline was s
COMMENT Saturday was a very exciting day! The donanemab Phase 2 study offers some of the most compelling evidence to date that amyloid reduction can slow clinical decline, albeit modestly, in early stages of AD. While we have seen a suggestion of similar results
COMMENT I am very encouraged. This trial met its prespecified primary endpoint, which I believe is a first for an anti-amyloid drug in our field. In addition, the growth of tau, measured by tau PET in the frontal lobes, was slowed; this provides evidence of disea
CONFERENCE COVERAGE SERIES Donanemab Confirms: Clearing Plaques Slows Decline—By a Bit Astroglial Markers Poised for Stardom? Shuttle Unloads More Gantenerumab Into the Brain N-Terminal Tau Antibodies Fade, Mid-Domain Ones Push to the Fore Where to Now, Phospho-Tau? Clinicians from
CONFERENCE COVERAGE 2021-03-19 Conference Coverage It has been clear for a while that anti-amyloid antibodies can sweep plaque from the brain, but until now the question of whether this slows cognitive decline has remained hotly contended. Despite some positive signals from four such a
CONFERENCE 2021-10-03 00:00:00-2021-10-07 00:00:00 Rome, Italy 03 October 2021 to 07 October 2021 Congress format may change to hybrid or fully virtual. View Conference Website 0
CONFERENCE COVERAGE 2021-03-19 Conference Coverage One person “checks out” from family, seeming reluctant to talk. Another talks incessantly, without saying much. One person seems unaware of the emotions of others; another recognizes emotions but doesn’t seem to care. The social and em
CONFERENCE 2022-04-12 00:00:00-2022-04-15 00:00:00 Leuven, Belgium 12 April 2022 to 15 April 2022 View Conference Website 0
CONFERENCE 2021-04-23 00:00:00-2021-04-23 00:00:00 Webinar 23 April 2021 Speakers: Kate Gordon and Clarissa Giebel View Conference Website 0
CONFERENCE 2021-04-22 00:00:00-2021-04-22 00:00:00 Webinar 22 April 2021 Speakers: Felix Clay and Joe Strong Time: 11:00 am ET View Conference Website 0
CONFERENCE 2021-04-16 00:00:00-2021-04-16 00:00:00 Webinar 16 April 2021 Speaker: Gene Bowman Time: 12 noon ET View Conference Website 0
University of New Mexico Health Sciences CenterAlbuquerque, United States
